GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Medpace Holdings Inc (FRA:01P) » Definitions » Piotroski F-Score

Medpace Holdings (FRA:01P) Piotroski F-Score : 7 (As of Mar. 30, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Medpace Holdings Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Medpace Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Medpace Holdings's Piotroski F-Score or its related term are showing as below:

FRA:01P' s Piotroski F-Score Range Over the Past 10 Years
Min: 6   Med: 7   Max: 8
Current: 7

During the past 12 years, the highest Piotroski F-Score of Medpace Holdings was 8. The lowest was 6. And the median was 7.


Medpace Holdings Piotroski F-Score Historical Data

The historical data trend for Medpace Holdings's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medpace Holdings Piotroski F-Score Chart

Medpace Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 7.00 7.00 8.00 7.00

Medpace Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 8.00 7.00

Competitive Comparison of Medpace Holdings's Piotroski F-Score

For the Diagnostics & Research subindustry, Medpace Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medpace Holdings's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Medpace Holdings's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 94.384 + 82.078 + 86.88 + 111.752 = €375 Mil.
Cash Flow from Operations was 140.463 + 108.133 + 134.317 + 182.086 = €565 Mil.
Revenue was 470.16 + 490.609 + 480.519 + 512.442 = €1,954 Mil.
Gross Profit was 142.731 + 142.916 + 152.276 + 170.293 = €608 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(1519.311 + 1652.126 + 1783.725 + 1877.739 + 2006.327) / 5 = €1767.8456 Mil.
Total Assets at the begining of this year (Dec23) was €1,519 Mil.
Long-Term Debt & Capital Lease Obligation was €121 Mil.
Total Current Assets was €983 Mil.
Total Current Liabilities was €1,055 Mil.
Net Income was 68.083 + 56.366 + 66.105 + 71.799 = €262 Mil.

Revenue was 405.425 + 425.381 + 461.472 + 457.034 = €1,749 Mil.
Gross Profit was 121.597 + 114.745 + 124.802 + 125.451 = €487 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(1276.755 + 1303.605 + 1298.604 + 1393.058 + 1519.311) / 5 = €1358.2666 Mil.
Total Assets at the begining of last year (Dec22) was €1,277 Mil.
Long-Term Debt & Capital Lease Obligation was €130 Mil.
Total Current Assets was €545 Mil.
Total Current Liabilities was €848 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Medpace Holdings's current Net Income (TTM) was 375. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Medpace Holdings's current Cash Flow from Operations (TTM) was 565. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=375.094/1519.311
=0.24688428

ROA (Last Year)=Net Income/Total Assets (Dec22)
=262.353/1276.755
=0.20548422

Medpace Holdings's return on assets of this year was 0.24688428. Medpace Holdings's return on assets of last year was 0.20548422. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Medpace Holdings's current Net Income (TTM) was 375. Medpace Holdings's current Cash Flow from Operations (TTM) was 565. ==> 565 > 375 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=120.553/1767.8456
=0.06819204

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=130.326/1358.2666
=0.09595024

Medpace Holdings's gearing of this year was 0.06819204. Medpace Holdings's gearing of last year was 0.09595024. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=982.914/1054.848
=0.93180629

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=544.54/848.345
=0.64188508

Medpace Holdings's current ratio of this year was 0.93180629. Medpace Holdings's current ratio of last year was 0.64188508. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Medpace Holdings's number of shares in issue this year was 31.876. Medpace Holdings's number of shares in issue last year was 31.847. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=608.216/1953.73
=0.31131016

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=486.595/1749.312
=0.27816364

Medpace Holdings's gross margin of this year was 0.31131016. Medpace Holdings's gross margin of last year was 0.27816364. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=1953.73/1519.311
=1.28593158

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=1749.312/1276.755
=1.37012348

Medpace Holdings's asset turnover of this year was 1.28593158. Medpace Holdings's asset turnover of last year was 1.37012348. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Medpace Holdings has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Medpace Holdings  (FRA:01P) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Medpace Holdings Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Medpace Holdings's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Medpace Holdings Business Description

Traded in Other Exchanges
Address
5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the us, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.

Medpace Holdings Headlines

No Headlines